Study record
MOTS-c, a mitochondrial-derived peptide, ameliorates lysosomal membrane permeability and improves survival of soft tissue transplantation
Shi J, Wu Y, Liu X et al. · Autophagy · 2026
What this study reported
Reported that administered MOTS-c was associated with greater flap survival, improved perfusion, more angiogenesis, reduced endothelial pyroptosis, increased autophagy and reduced lysosomal membrane permeabilisation in ischemic mouse flaps. Reported that MOTS-c suppressed PLA2G4A phosphorylation through MAPK1-MAPK3-NFKB signalling, with PLA2G4A overexpression reversing these changes.
Limitations
Male mice only with group sizes not reported in the abstract; a single surgical ischemia model; mechanism inferred from overexpression rather than genetic deletion.
Study record
| Study model | Animal study (in vivo) |
|---|---|
| Substance studied | MOTS-c administeredSynthetic MOTS-c was given to cells, animals or people. |
| Species | mouse, human |
| System studied | Ischemic skin flaps in male C57BL/6 mice with AAV-mediated PLA2G4A overexpression; endothelial cells in culture |
| Population | Not reported |
| Design | Controlled animal experiment with RNA sequencing and cell culture experiments |
| Sample size as reported | not reported |
| Control group | untreated ischemic flap animals |
| Route (data field only) | Not reported |
| Endpoints measured | flap survival; blood flow perfusion; angiogenesis and collagen remodelling; endothelial pyroptosis; autophagy and lysosomal membrane permeabilisation; MAPK1-MAPK3-NFKB and PLA2G4A signalling |
| Pathways measured | Autophagy / mitophagy · MAPK signalling · Inflammation · Oxidative stress |
| Research areas | Cardiovascular · Mitochondrial biology · Inflammation & immunity |
| Evidence tier | C — Animal in vivo |
| Publication types | Journal Article |
Appraisal
Each dimension is recorded separately and never combined into a single score. A study can be well controlled and still tell you little about people.
- Relevance to MOTS-c
- Direct
- Model applicability
- Mammalian
- Sample size
- Not reported
- Controls
- Appropriate
- Outcome validity
- Surrogate
- Support for its own conclusion
- Moderate
Provenance
- Bibliographic fields retrieved from PubMed E-utilities efetch (title, journal, date, authors, DOI) on 2026-11-11.
- Annotated from the published abstract.
- Editorial review: approved (2026-11-11).
- Classification follows the site methodology; the record describes the study, not what MOTS-c does in people.